I-Mab to Start China Phase II Trial of Immunotherapy for GBM

I-Mab, a Shanghai biopharma, announced approval to start a China Phase II trial of a novel long-acting recombinant human interleukin-7 (rhIL-7) in lymphopenic patients with glioblastoma multiforme (GBM). In late 2017, I-Mab in-licensed China rights to TJ107/HyLeukin-7™ (efineptakin alfa) from Korea's Genexine in a deal worth up to $548 million. An immunotherapy, HyLeukin is based on interleukin-7, a factor in the proliferation and homeostasis of T cells. More details.... Stock Symbols: (NSDQ: IMAB) (KOSDAQ: 095700) Share this with colleagues: // //